Patient P-02373
Therapy response
Unstable
Tolerance
Favorable
GI state
Favorable
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
19%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S09
- Day 21 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 21.
Primary contributors, last 14 days
- Nutritional resilience-10
- Treatment adherence+9
- Inflammatory activity+5
- GI instability+4
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable78 min
stable · +2.1 vs previous 14 d
Sleep duration
Wearable5.7 h
stable · -0.1 vs previous 14 d
Energy level
Daily log5.6/10
stable · -0.2 vs previous 14 d
Steps
Wearable9,087
stable · -8 vs previous 14 d
GI burden
Companion21/100
worsening · +1.8 vs previous 14 d
Adherence
Companion90.1 %
stable · +0.5 vs previous 14 d
Sleep quality
Wearable19.1/100
worsening · -3.0 vs previous 14 d
Glucose, CGM daily mean
CGM135 mg/dL
stable · -1.3 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 62 from the failing basin, 51 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -4.6 next day on high-intake days · n 19
Would not help
- BR-03 Behavioural Recommendationonly 22% improved among 9 similar
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-4.6supporter · 95%
- Caffeine-2.4no signal · 54%
- Ultra-processed food+1.6no signal · 38%
- Alcohol-0.9no signal · 19%
- Simple carbohydrates+0.5no signal · 15%
- Insoluble fibre+0.5no signal · 15%
- Dietary fat load-0.2no signal · 15%
- Histamine load-0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Autonomic recovery ↓45
- WearableResting HR 75 bpm
- WearableShort sleep window
- Mucosal barrier integrity ↓40
- MicrobiomeAkkermansia low → thinner mucus layer
- WearableSleep 5.7 h, below personal baseline
- Inflammatory signalling ↑15
- WearableHRV 31 ms, trending down
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
Microbiome
Shannon diversity 4.1 · butyrate capacity 66/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 34 ms
- Sleep
- 6.0 h
- Steps
- 9,022
- Resting HR
- 71 bpm
Daily log: GI score 21, nutritional resilience 59, adherence 90.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02564 | 41% | S15 | BR-03 | improved | 32 |
| P-02016 | 38% | S20 | DT-01 | improved | 27 |
| P-02033 | 31% | S06 | GI-04 | improved | 51 |
| P-02037 | 31% | S04 | GI-04 | improved | 53 |
| P-02331 | 31% | S14 | BR-03 | improved | 34 |
| P-02150 | 30% | S11 | HY-01 | improved | 45 |
| P-02339 | 30% | S03 | DT-01 | improved | 50 |
| P-02391 | 30% | S19 | HY-01 | improved | 53 |
| P-02455 | 30% | S09 | DT-01 | improved | 50 |
| P-02494 | 30% | S09 | GI-04 | improved | 47 |
| P-02031 | 29% | S12 | AD-05 | improved | 47 |
| P-02223 | 29% | S20 | HY-01 | improved | 49 |